Related Experiment Video
Updated: Jul 14, 2026
A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026
Salivary Methotrexate as a Predictor of Oral Mucositis in Hematological Cancer Patients: A Phase II Randomized,
Letícia Rodrigues-Oliveira1,2, Carolina Guimarães Bonfim2, Ana Leticia Mores1
1Oral Diagnosis Department, Faculdade de Odontologia de Piracicaba, Universidade de Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Objective:
To evaluate the efficacy of prophylactic photobiomodulation therapy (PBMT) in preventing oral mucositis (OM) and to assess serum and salivary methotrexate (MTX) levels as predictors of OM in adults receiving high-dose methotrexate (HD-MTX).
Methods:
This phase II randomized, double-blind, placebo-controlled trial enrolled adults with hematological malignancies undergoing a first HD-MTX cycle at a tertiary cancer center in Brazil. Participants were randomized to PBMT or sham laser therapy, administered daily until MTX clearance or for up to five sessions. OM was assessed for 9 days using WHO criteria. Serum and salivary MTX concentrations were measured at 24, 48, and 72 h post-infusion, along with urinary pH and serum creatinine.
Results:
Fifty-three patients were randomized (PBMT n = 26; placebo n = 27). PBMT significantly reduced ulcerative OM (grade ≥ 2) at 96 h (11.5% vs. 51.9%), yielding a 77.7% relative risk reduction and a number needed to treat of 2 (p < 0.01). Placebo recipients had an 8.97-fold higher odds of severe OM. Serum MTX was not associated with OM, whereas salivary MTX increased disproportionately over time and independently correlated with OM severity.
Conclusions:
PBMT significantly reduced OM incidence and severity in adults receiving HD-MTX. Salivary MTX is a promising non-invasive biomarker for OM risk.
Trial Registration:
Trial was prospectively registered in the Brazilian Registry of Clinical Trials (ReBec, No. 12218).
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
01:17Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...